<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00373880</url>
  </required_header>
  <id_info>
    <org_study_id>4741</org_study_id>
    <nct_id>NCT00373880</nct_id>
  </id_info>
  <brief_title>Effects of Aripiprazole on Cocaine Craving and Self-Administration</brief_title>
  <official_title>Effects of Aripiprazole on Cocaine Craving and Self-Administration</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>New York State Psychiatric Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>New York State Psychiatric Institute</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate whether aripiprazole will decrease cocaine
      self-administration, subjective effects and cravings compared to placebo.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Despite the recent increase in data about cocaine's basic neurochemical mechanisms of action,
      progress towards the development of an effective pharmacological treatment for cocaine abuse
      has been disappointing. We are proposing to use our laboratory model of repeated dose cocaine
      self-administration to assess the potential efficacy of the novel antipsychotic,
      aripiprazole. Aripiprazole is a partial agonist at both the dopamine D2 receptor and at the
      serotonin 5HT1a receptor, while antagonizing the 5HT2a receptor. By functioning as a partial
      D2 agonist, aripiprazole is hypothesized to function as a D2 antagonist during
      hypodopaminergic states, such as during cocaine use, while functioning as a D2 agonist during
      hypodopaminergic states, such as during cocaine withdrawal. This 42-day,
      outpatient/inpatient/outpatient/inpatient protocol will evaluate the effects of aripiprazole
      maintenance (0, 15 mg/day) on cocaine craving, subjective effects, and self-administration
      using a within-subjects design. Non-treatment seeking cocaine abusers will be maintained
      outpatient for 16 days of dose maintenance prior to inpatient cocaine self-administration
      sessions. During the inpatient phases, volunteers will live on a hospital clinical research
      unit and will participate in laboratory sessions in which they will have the opportunity to
      choose between repeated doses of smoked cocaine and $5. In addition to measuring their
      cocaine self-administration, we will measure the cardiovascular and subjective effects of
      cocaine under each aripiprazole maintenance condition.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2005</start_date>
  <completion_date type="Actual">September 2008</completion_date>
  <primary_completion_date type="Actual">August 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>In order to achieve steady-state concentrations, participants (n=8 men) were administered placebo and aripiprazole (15 mg/day) capsules in counter-balanced order for 21 days. A smoked cocaine dose-response curve (0, 12, 25, 50 mg) was determined twice under placebo and aripiprazole maintenance.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cocaine Self-administration</measure>
    <time_frame>5 days</time_frame>
    <description>Mean number of cocaine choices as a function of cocaine dose and aripiprazole dose (n=8).
Participants sampled the dose of cocaine available for the session and then had five choices to respond for money ($5.00) or cocaine using a modified progressive-ratio schedule.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Subjective Effects of Cocaine</measure>
    <time_frame>5 days</time_frame>
    <description>Mean Visual Analog Scale (VAS) ratings (items: &quot;Quality&quot;, &quot;Pay for Dose&quot;, &quot;Good Drug Effect&quot;, and &quot;Cocaine Craving&quot;) from 0-100mm as a function of cocaine dose and aripiprazole dose 4 min following a single administration of cocaine (the &quot;sample dose&quot;) at the start of the session.
For &quot;Quality&quot; item, the perceived quality of the drug is rated. The higher the rating, the better quality the drug was perceived to be.
For &quot;Pay for Dose&quot; item, the likelihood that the participant would pay for the drug is indicated. Higher ratings indicate a better likelihood that the person would pay for the dose received.
For &quot;Good Drug Effect&quot;, the likelihood of feeling a good drug effect is indicated. The higher the number, the more of a good drug effect the person reported.
For &quot;Cocaine Craving&quot;, the intensity of craving is reported. Higher scores indicate more craving for cocaine.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Cocaine</measure>
    <time_frame>8 minutes</time_frame>
    <description>Mean plasma cocaine levels after a single administration of each cocaine dose as a function of aripiprazole and cocaine dose.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">26</enrollment>
  <condition>Cocaine Abuse</condition>
  <arm_group>
    <arm_group_label>Aripiprazole (15mg) + Cocaine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Aripiprazole (15 mg/day) in conjunction with a smoked cocaine dose-response curve (0, 12, 25, 50 mg).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo + Cocaine</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo (0 mg/day) in conjunction with a smoked cocaine dose-response curve (0, 12, 25, 50 mg)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aripiprazole + Cocaine</intervention_name>
    <description>Participants received aripiprazole (15mg/day) in conjunction with a dose-response of cocaine (0, 12, 25, 50 mg).</description>
    <arm_group_label>Aripiprazole (15mg) + Cocaine</arm_group_label>
    <other_name>Active</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo + Cocaine</intervention_name>
    <description>Placebo (0 mg/day) in conjunction with a dose-response of cocaine (0, 12, 25, 50 mg).</description>
    <arm_group_label>Placebo + Cocaine</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Meets DSM-IV criteria for current cocaine abuse

          -  Average use of smoked cocaine is at least 2x/week for past 6 mos); currently spends at
             least $70 per week on cocaine

          -  Has patterns of smoked cocaine use in terms of frequency and amounts which parallel or
             exceed those administered in the study

          -  Age 21-45

          -  Able to give informed consent, and comply with study procedures

        Exclusion Criteria:

          -  Current seizure disorder, heart disease or psychiatric disorders (other than cocaine
             dependence)

          -  Dependence on substances other than cocaine or nicotine

          -  Request for drug treatment

          -  Judged to be noncompliant with study protocol

          -  Current use of any medication that has the potential to interact with aripiprazole
             (i.e., seizure medications, anti-fungal medications, cardiac medications, or
             medication that produces drowsiness)

          -  Clinical laboratory tests outside normal limits that are clinically unacceptable to
             the study physician (BP &gt; 140/90; BUN, creatinine, LFTs &gt; 1.5 ULN; hematocrit &lt; 34 for
             women, &lt; 36 for men; pseudocholinesterase deficiency)

          -  Currently meeting DSM-IV criteria for all major psychiatric/psychotic disorders other
             than transient psychosis due to drug abuse

          -  Current parole or probation

          -  History of significant violent or suicidal behavior
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Margaret Haney, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>New York State Psychiatric Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Irving Center for Clinical Research</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 7, 2006</study_first_submitted>
  <study_first_submitted_qc>September 7, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 8, 2006</study_first_posted>
  <results_first_submitted>August 3, 2017</results_first_submitted>
  <results_first_submitted_qc>September 5, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">September 11, 2017</results_first_posted>
  <last_update_submitted>September 5, 2017</last_update_submitted>
  <last_update_submitted_qc>September 5, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 11, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Aripiprazole</keyword>
  <keyword>Cocaine abuse</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cocaine-Related Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aripiprazole</mesh_term>
    <mesh_term>Cocaine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Aripiprazole/Placebo, Cocaine</title>
          <description>aripiprazole (15 mg/day) or placebo (0mg/day) + smoked cocaine dose–response curve (0, 12, 25, 50 mg)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Arrested</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Aripiprazole vs. Placebo</title>
          <description>Aripiprazole + Cocaine: Participants received aripiprazole (15mg/day) or placebo (o mg/day) in conjunction with a dose-response of cocaine (0, 12, 25, 50 mg).</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="8"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41.8" spread="3.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Cocaine Self-administration</title>
        <description>Mean number of cocaine choices as a function of cocaine dose and aripiprazole dose (n=8).
Participants sampled the dose of cocaine available for the session and then had five choices to respond for money ($5.00) or cocaine using a modified progressive-ratio schedule.</description>
        <time_frame>5 days</time_frame>
        <population>Eight participants were included in this within-subjects analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo + 0mg Cocaine</title>
            <description>Participants received placebo (0 mg/day) in conjunction with 0 mg cocaine.</description>
          </group>
          <group group_id="O2">
            <title>Placebo + 12mg Cocaine</title>
            <description>Participants received placebo (0 mg/day) in conjunction with 12 mg cocaine.</description>
          </group>
          <group group_id="O3">
            <title>Placebo + 25mg Cocaine</title>
            <description>Participants received placebo (0 mg/day) in conjunction with 25 mg cocaine.</description>
          </group>
          <group group_id="O4">
            <title>Placebo + 50mg Cocaine</title>
            <description>Participants received placebo (0 mg/day) in conjunction with 50 mg cocaine.</description>
          </group>
          <group group_id="O5">
            <title>Aripiprazole + 0 mg Cocaine</title>
            <description>Participants received aripiprazole (15 mg/day) in conjunction with 0 mg cocaine.</description>
          </group>
          <group group_id="O6">
            <title>Aripiprazole + 12mg Cocaine</title>
            <description>Participants received aripiprazole (15 mg/day) in conjunction with 12 mg cocaine.</description>
          </group>
          <group group_id="O7">
            <title>Aripiprazole + 25mg Cocaine</title>
            <description>Participants received aripiprazole (15 mg/day) in conjunction with 25 mg cocaine.</description>
          </group>
          <group group_id="O8">
            <title>Aripiprazole + 50mg Cocaine</title>
            <description>Participants received aripiprazole (15 mg/day) in conjunction with 50 mg cocaine.</description>
          </group>
        </group_list>
        <measure>
          <title>Cocaine Self-administration</title>
          <description>Mean number of cocaine choices as a function of cocaine dose and aripiprazole dose (n=8).
Participants sampled the dose of cocaine available for the session and then had five choices to respond for money ($5.00) or cocaine using a modified progressive-ratio schedule.</description>
          <population>Eight participants were included in this within-subjects analysis.</population>
          <units>Number of Choices</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="8"/>
                <count group_id="O6" value="8"/>
                <count group_id="O7" value="8"/>
                <count group_id="O8" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="0"/>
                    <measurement group_id="O2" value="1.5" spread="0.5"/>
                    <measurement group_id="O3" value="3" spread="0.5"/>
                    <measurement group_id="O4" value="4" spread="0.5"/>
                    <measurement group_id="O5" value="0.2" spread="0.1"/>
                    <measurement group_id="O6" value="2.8" spread="0.5"/>
                    <measurement group_id="O7" value="3.9" spread="0.5"/>
                    <measurement group_id="O8" value="3.7" spread="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Subjective Effects of Cocaine</title>
        <description>Mean Visual Analog Scale (VAS) ratings (items: &quot;Quality&quot;, &quot;Pay for Dose&quot;, &quot;Good Drug Effect&quot;, and &quot;Cocaine Craving&quot;) from 0-100mm as a function of cocaine dose and aripiprazole dose 4 min following a single administration of cocaine (the “sample dose”) at the start of the session.
For &quot;Quality&quot; item, the perceived quality of the drug is rated. The higher the rating, the better quality the drug was perceived to be.
For &quot;Pay for Dose&quot; item, the likelihood that the participant would pay for the drug is indicated. Higher ratings indicate a better likelihood that the person would pay for the dose received.
For &quot;Good Drug Effect&quot;, the likelihood of feeling a good drug effect is indicated. The higher the number, the more of a good drug effect the person reported.
For &quot;Cocaine Craving&quot;, the intensity of craving is reported. Higher scores indicate more craving for cocaine.</description>
        <time_frame>5 days</time_frame>
        <population>Eight participants were included in this within-subjects analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo + 0mg Cocaine</title>
            <description>Participants received placebo (0 mg/day) in conjunction with 0 mg cocaine.</description>
          </group>
          <group group_id="O2">
            <title>Placebo + 12mg Cocaine</title>
            <description>Participants received placebo (0 mg/day) in conjunction with 12 mg cocaine.</description>
          </group>
          <group group_id="O3">
            <title>Placebo + 25mg Cocaine</title>
            <description>Participants received placebo (0 mg/day) in conjunction with 25 mg cocaine.</description>
          </group>
          <group group_id="O4">
            <title>Placebo + 50mg Cocaine</title>
            <description>Participants received placebo (0 mg/day) in conjunction with 50 mg cocaine.</description>
          </group>
          <group group_id="O5">
            <title>Aripiprazole + 0 mg Cocaine</title>
            <description>Participants received aripiprazole (15 mg/day) in conjunction with 0 mg cocaine.</description>
          </group>
          <group group_id="O6">
            <title>Aripiprazole + 12mg Cocaine</title>
            <description>Participants received aripiprazole (15 mg/day) in conjunction with 12 mg cocaine.</description>
          </group>
          <group group_id="O7">
            <title>Aripiprazole + 25mg Cocaine</title>
            <description>Participants received aripiprazole (15 mg/day) in conjunction with 25 mg cocaine.</description>
          </group>
          <group group_id="O8">
            <title>Aripiprazole + 50mg Cocaine</title>
            <description>Participants received aripiprazole (15 mg/day) in conjunction with 50 mg cocaine.</description>
          </group>
        </group_list>
        <measure>
          <title>Subjective Effects of Cocaine</title>
          <description>Mean Visual Analog Scale (VAS) ratings (items: &quot;Quality&quot;, &quot;Pay for Dose&quot;, &quot;Good Drug Effect&quot;, and &quot;Cocaine Craving&quot;) from 0-100mm as a function of cocaine dose and aripiprazole dose 4 min following a single administration of cocaine (the “sample dose”) at the start of the session.
For &quot;Quality&quot; item, the perceived quality of the drug is rated. The higher the rating, the better quality the drug was perceived to be.
For &quot;Pay for Dose&quot; item, the likelihood that the participant would pay for the drug is indicated. Higher ratings indicate a better likelihood that the person would pay for the dose received.
For &quot;Good Drug Effect&quot;, the likelihood of feeling a good drug effect is indicated. The higher the number, the more of a good drug effect the person reported.
For &quot;Cocaine Craving&quot;, the intensity of craving is reported. Higher scores indicate more craving for cocaine.</description>
          <population>Eight participants were included in this within-subjects analysis.</population>
          <units>Scores on a scale of 0-100mm</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="8"/>
                <count group_id="O6" value="8"/>
                <count group_id="O7" value="8"/>
                <count group_id="O8" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Quality</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="0"/>
                    <measurement group_id="O2" value="8.5" spread="0.5"/>
                    <measurement group_id="O3" value="32" spread="5"/>
                    <measurement group_id="O4" value="38.5" spread="6"/>
                    <measurement group_id="O5" value="0" spread="0"/>
                    <measurement group_id="O6" value="10" spread="0.4"/>
                    <measurement group_id="O7" value="25" spread="5"/>
                    <measurement group_id="O8" value="37" spread="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pay for Dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="0"/>
                    <measurement group_id="O2" value="1.4" spread="0.5"/>
                    <measurement group_id="O3" value="5" spread="1"/>
                    <measurement group_id="O4" value="5.75" spread="1"/>
                    <measurement group_id="O5" value="0" spread="0"/>
                    <measurement group_id="O6" value="1.6" spread="0.2"/>
                    <measurement group_id="O7" value="2.9" spread="0.3"/>
                    <measurement group_id="O8" value="6" spread="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Good Drug Effect</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" spread="0.1"/>
                    <measurement group_id="O2" value="11" spread="2"/>
                    <measurement group_id="O3" value="29" spread="5"/>
                    <measurement group_id="O4" value="42" spread="5"/>
                    <measurement group_id="O5" value="2" spread="0.1"/>
                    <measurement group_id="O6" value="16" spread="3"/>
                    <measurement group_id="O7" value="30.5" spread="5"/>
                    <measurement group_id="O8" value="35" spread="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cocaine Craving</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20" spread="5"/>
                    <measurement group_id="O2" value="28" spread="5"/>
                    <measurement group_id="O3" value="30" spread="5"/>
                    <measurement group_id="O4" value="38.5" spread="5"/>
                    <measurement group_id="O5" value="26" spread="6"/>
                    <measurement group_id="O6" value="30" spread="5"/>
                    <measurement group_id="O7" value="36" spread="6"/>
                    <measurement group_id="O8" value="33.5" spread="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Cocaine</title>
        <description>Mean plasma cocaine levels after a single administration of each cocaine dose as a function of aripiprazole and cocaine dose.</description>
        <time_frame>8 minutes</time_frame>
        <population>Eight participants were included in this within-subjects analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo + 0mg Cocaine</title>
            <description>Participants received placebo (0 mg/day) in conjunction with 0 mg cocaine.</description>
          </group>
          <group group_id="O2">
            <title>Placebo + 12mg Cocaine</title>
            <description>Participants received placebo (0 mg/day) in conjunction with 12 mg cocaine.</description>
          </group>
          <group group_id="O3">
            <title>Placebo + 25mg Cocaine</title>
            <description>Participants received placebo (0 mg/day) in conjunction with 25 mg cocaine.</description>
          </group>
          <group group_id="O4">
            <title>Placebo + 50mg Cocaine</title>
            <description>Participants received placebo (0 mg/day) in conjunction with 50 mg cocaine.</description>
          </group>
          <group group_id="O5">
            <title>Aripiprazole + 0 mg Cocaine</title>
            <description>Participants received aripiprazole (15 mg/day) in conjunction with 0 mg cocaine.</description>
          </group>
          <group group_id="O6">
            <title>Aripiprazole + 12mg Cocaine</title>
            <description>Participants received aripiprazole (15 mg/day) in conjunction with 12 mg cocaine.</description>
          </group>
          <group group_id="O7">
            <title>Aripiprazole + 25mg Cocaine</title>
            <description>Participants received aripiprazole (15 mg/day) in conjunction with 25 mg cocaine.</description>
          </group>
          <group group_id="O8">
            <title>Aripiprazole + 50mg Cocaine</title>
            <description>Participants received aripiprazole (15 mg/day) in conjunction with 50 mg cocaine.</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Cocaine</title>
          <description>Mean plasma cocaine levels after a single administration of each cocaine dose as a function of aripiprazole and cocaine dose.</description>
          <population>Eight participants were included in this within-subjects analysis.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="8"/>
                <count group_id="O6" value="8"/>
                <count group_id="O7" value="8"/>
                <count group_id="O8" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32" spread="2"/>
                    <measurement group_id="O2" value="60" spread="4"/>
                    <measurement group_id="O3" value="67" spread="4"/>
                    <measurement group_id="O4" value="119" spread="12"/>
                    <measurement group_id="O5" value="18" spread="1"/>
                    <measurement group_id="O6" value="36" spread="3"/>
                    <measurement group_id="O7" value="75" spread="5"/>
                    <measurement group_id="O8" value="130" spread="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>2 years</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Aripiprazole vs. Placebo</title>
          <description>Aripiprazole + Cocaine: Participants received aripiprazole (15mg/day) in conjunction with a dose-response of cocaine (0, 12, 25, 50 mg).</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo + Cocaine: Participants received placebo (0 mg/day) in conjunction with a dose-response of cocaine (0, 12, 25, 50 mg).</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The study did not assess whether the medication would be useful in preventing relapse in abstinent cocaine users or whether aripiprazole would be beneficial to cocaine-dependent individuals being treated for a psychiatric comorbidity.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Margaret Haney, Ph.D.</name_or_title>
      <organization>New York State Psychiatric Institute at Columbia University Medical Center</organization>
      <phone>646-774-6153</phone>
      <email>meg.haney@nyspi.columbia.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

